What Makes Biogen (BIIB) an Attractive Long-Term Holding?

1 week ago 5

Soumya Eswaran

Thu, March 5, 2026 astatine 7:36 AM CST 3 min read

Patient Capital Management, a worth investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In Q4 2025, Patient Opportunity Equity Strategy returned 5.99% nett of fees, compared to its unmanaged benchmark, the S&P 500 Index, which returned 2.65%. Through a three-factor show attribution model, the portfolio's outperformance was attributed to allocation, selection, and enactment effects. The marketplace ended a beardown twelvemonth with 17.9% returns, marking the seventh-best three-year play successful marketplace history. 2025 was a twelvemonth of AI, extending the benefits to hardware, energy, and constituent suppliers crossed the ecosystem. Seven stocks accounted for implicit fractional of the S&P 500’s returns, posing difficulties for progressive managers. Nevertheless, the strategy performed well, outperforming the S&P 500 for the 3rd consecutive twelvemonth with a instrumentality of 26.1%. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Patient Opportunity Equity Strategy highlighted Biogen Inc. (NASDAQ:BIIB). Biogen Inc. (NASDAQ:BIIB) is simply a biotechnology institution specializing successful processing therapies for neurological and neurodegenerative diseases. On March 04, 2026, Biogen Inc. (NASDAQ:BIIB) banal closed astatine $189.94 per share. One-month instrumentality of Biogen Inc. (NASDAQ:BIIB) was 2.47%, and its shares gained 28.89% implicit the past 52 weeks. Biogen Inc. (NASDAQ:BIIB) has a marketplace capitalization of $27.88 billion.

Patient Opportunity Equity Strategy stated the pursuing regarding Biogen Inc. (NASDAQ:BIIB) successful its 4th fourth 2025 capitalist letter:

"This 4th we entered 3 caller positions and exited 1 position. We accrued our vulnerability to Biogen Inc. (NASDAQ:BIIB) successful the 4th by buying long-dated telephone options expiring successful 2028 with a onslaught terms of $150. We proceed to deliberation Biogen is an charismatic plus implicit the agelong term. The institution has a fig of late-stage pipeline assets that should scope the marketplace implicit the adjacent fewer years, astatine the aforesaid clip that its Alzheimer’s franchise should proceed to ramp arsenic blood-based biomarkers and subcutaneous injections broaden the imaginable treatable universe. Longer term, we judge Biogen is positioning itself to ain aggregate stages of the Alzheimer’s illness lifecycle, akin to its humanities attack successful aggregate sclerosis. With a cleaned-up outgo structure, a much focused probe effort, and a increasing late-stage pipeline, we proceed to presumption the risk/reward arsenic attractive."

Read Entire Article